Most side effects of letrozole begin to ease within weeks to months of stopping, though some changes take longer to reverse and a few may persist. After years of suppressing estrogen to starve hormone-receptor-positive breast cancer cells, your body has to recalibrate. Bones that lost density start to regain some of it, joint stiffness gradually fades, and cognitive sharpness tends to improve. But the transition is not instant, and some women find new concerns replace old ones, particularly around recurrence risk and the question of whether they stopped treatment at the right time.
What Happens to Your Bones
Bone loss is one of the most measurable consequences of aromatase inhibitor therapy. Letrozole works by blocking the enzyme that converts other hormones into estrogen, and estrogen plays a protective role in maintaining bone density. Over a typical five-year course, women on aromatase inhibitors lose measurably more bone than they would from normal aging alone. The good news is that stopping treatment allows partial recovery, though the pattern depends on where in the skeleton you look.
A ten-year follow-up from the BREX study tracked what happened after women discontinued their aromatase inhibitor. At the lumbar spine, bone mineral density actually increased by about 2.6% over the first five years off treatment. At the femoral neck (the hip), bone density continued to decline, but at roughly one-third the rate seen in women who stayed on therapy.
1PubMed Central. Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX studyResults from the IBIS-II prevention trial, which used a different aromatase inhibitor (anastrozole), found a similar spine rebound. Women who had been on the drug gained about 1.25% in lumbar spine density within two years of stopping, while women who had been on placebo showed almost no change at the spine over the same period. Hip density, by contrast, stabilized rather than continuing to fall, which was itself a meaningful improvement over the on-treatment trajectory.
2British Journal of Cancer. Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trialThe practical takeaway: your spine is likely to recover some lost ground after you stop, while your hips may stabilize but not bounce back as readily. If you were started on a bone-protective medication like a bisphosphonate during treatment, your oncologist will reassess whether to continue it. Either way, a bone density scan shortly after completing letrozole gives you and your care team a useful baseline for tracking recovery.
Joint Pain and Musculoskeletal Symptoms
Joint stiffness and aching, sometimes called aromatase inhibitor-associated musculoskeletal symptoms, rank among the most disruptive side effects during treatment. These symptoms are a leading reason women stop their medication early. In one study, worsening musculoskeletal symptoms carried the strongest association with early discontinuation of aromatase inhibitor therapy, more than mood changes, cognitive complaints, or concerns about weight.
3PubMed Central. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast CancerMost women notice meaningful improvement in joint symptoms within a few weeks to a couple of months after their last dose. The exact mechanism behind aromatase inhibitor joint pain is still not fully understood, which has made it hard to study targeted treatments. A Cochrane review of exercise therapies for these symptoms noted the lack of a single clear definition of the condition and called for better-designed trials to test specific exercise interventions.
4PubMed Central. Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancerEven without a precise understanding of the mechanism, the clinical pattern is consistent: the pain is tied to estrogen suppression, and when that suppression lifts, the pain lessens. If you still have lingering joint symptoms several months after stopping, it is worth discussing with your doctor, because other causes like osteoarthritis or vitamin D deficiency can coexist and may have been masked by the blanket assumption that everything was aromatase inhibitor-related.
Cognitive Sharpness and Mood
Many women on letrozole describe a mental fog, difficulty finding words, or a feeling that their thinking has slowed. This is not imagined. The BIG 1-98 cognitive function substudy formally tested women during and after endocrine therapy. About a year after women stopped taking either letrozole or tamoxifen, the researchers found significant improvement in cognition across all tested tasks. The effect size was moderate for overall cognitive recovery.
5PubMed Central. Do aromatase inhibitors have adverse effects on cognitive function?One important limitation: that study did not measure cognition before women started endocrine therapy, so researchers could not say whether women fully returned to their pre-treatment baseline or just improved from their on-treatment state. Still, the consistent improvement across multiple cognitive domains after stopping treatment suggests that the effect of letrozole on thinking is at least partly reversible. If you feel like your mental clarity does not fully return, you are not necessarily wrong. Some degree of cognitive change may persist, particularly in women who underwent chemotherapy before starting letrozole, since chemotherapy carries its own cognitive effects that can compound the picture.
Mood tends to follow a similar trajectory. During treatment, women report higher rates of depressed mood, irritability, and emotional flatness. Many of these symptoms track with estrogen suppression and begin to lift as estrogen levels recover. The timeline varies widely from person to person, and women who had a history of depression or anxiety before their diagnosis may find those conditions resurface in the post-treatment period regardless of hormonal shifts.
Sexual and Urogenital Health
Estrogen deprivation hits the urogenital tract hard. Vaginal dryness, pain during intercourse, recurrent urinary tract infections, and decreased sexual interest are common complaints during aromatase inhibitor therapy. These symptoms arise because the vaginal and urethral tissues depend on estrogen to maintain their thickness, elasticity, and moisture.
6PubMed Central. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapyAfter stopping letrozole, estrogen levels begin to rise back to normal postmenopausal levels, which are already low compared with premenopausal levels. Recovery of urogenital tissue can be slow. Some women notice improvement within a few months; others find that years of atrophy take longer to reverse, and in some cases the tissue does not fully recover on its own. Non-hormonal moisturizers and lubricants remain the first-line approach. For persistent symptoms, low-dose vaginal estrogen is sometimes considered, but that conversation requires careful evaluation of your cancer history and should be led by your oncologist.
Sexual desire is more complicated than tissue health alone. Fatigue, body image changes from treatment, relationship strain, and the psychological weight of a cancer diagnosis all feed into libido. The lifting of estrogen suppression helps the physical component, but do not be surprised if the psychological side takes its own timeline.
Weight and Body Composition
Many women blame letrozole for weight gain, and it is a persistent concern. The evidence, however, suggests that aromatase inhibitors themselves are not a major driver of weight change. A large analysis from the IBIS-II trial compared body weight, body fat, and fat-free mass between women on an aromatase inhibitor and women on placebo over more than five years. The differences were tiny and not statistically significant. The aromatase inhibitor group weighed roughly the same as the placebo group at every measured time point, including after five or more years.
7PubMed Central. Body composition changes during breast cancer preventive treatment with anastrozole: Findings from the IBIS-II trialThis does not mean your experience of weight gain is not real. It means the cause is more likely a combination of aging, reduced physical activity during treatment, changes in metabolism related to menopause, and possibly the aftereffects of chemotherapy rather than the aromatase inhibitor itself. When you stop letrozole, you should not expect a sudden drop in weight simply because you stopped the drug. What you may find is that improved energy and reduced joint pain make it easier to be more active, which can shift the equation over time.
Cholesterol and Heart Health
Estrogen has a modest protective effect on cardiovascular health, and suppressing it raises theoretical concerns about cholesterol. Studies on letrozole’s impact on lipid levels have been somewhat reassuring. In postmenopausal women with metastatic breast cancer treated with letrozole, total cholesterol, HDL, and LDL showed only small, non-significant fluctuations over months of treatment, with values returning toward baseline. The overall assessment was that letrozole had a safe effect on lipid profiles.
8PubMed Central. Effect of letrozole on plasma lipids, triglycerides, and estradiol in postmenopausal women with metastatic breast cancerAfter stopping, estrogen levels rise back to their natural postmenopausal range, which provides whatever cardiovascular benefit that modest estrogen level confers. If your cholesterol was being monitored during treatment and showed adverse trends, it is reasonable to recheck it a few months after stopping. Most women will not see dramatic shifts in either direction, but the post-treatment period is a good time to focus on the lifestyle factors that matter far more for heart health than any hormonal fluctuation: staying physically active, managing blood pressure, and eating well.
Hair Thinning and Recovery
Hair thinning during endocrine therapy is a quietly frustrating side effect that gets less attention than it deserves. It is not the dramatic hair loss of chemotherapy but rather a diffuse thinning that can affect how hair looks and feels. Aromatase inhibitors and tamoxifen are both linked to this, and it has been described as a largely unresolved therapeutic issue because so few studies have investigated specific treatments. Some evidence points to topical treatments and supplementation with vitamin C and omega-3 fatty acids as potentially helpful approaches that do not interfere with breast cancer outcomes.
9PubMed Central. Management of hair loss associated with endocrine therapy in patients with breast cancer: an overviewAfter stopping letrozole, many women notice that their hair begins to thicken again over several months, though the regrowth timeline is slow because hair grows in cycles. If you were already postmenopausal when you started treatment, your hair may not return to its pre-treatment fullness because some of the thinning is age-related and was happening independently of the drug. Patience is the main prescription here, and if thinning persists well past a year off treatment, checking thyroid function and iron levels is a reasonable step.
Should You Have Stayed On Longer?
This question haunts many women after finishing their prescribed course. The standard duration for aromatase inhibitor therapy is five years, but some women are offered extended therapy lasting seven, eight, or even ten years. The evidence on whether longer is better is nuanced and depends on individual risk factors.
In the MA.17 trial, extending treatment with letrozole after five years of endocrine therapy reduced the residual risk of recurrence by about 42% compared with placebo, and the benefit held regardless of whether women had lymph node involvement.
10PubMed Central. Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy That sounds like a clear win for longer treatment, but more recent data has added important caveats. A systematic review and network meta-analysis found that in the general population of breast cancer patients, extending aromatase inhibitor therapy by five extra years did not produce significantly better disease-free survival compared with extending by just two to four years. The benefit of a full five extra years was concentrated in specific groups, particularly women who had node-positive disease and those who had initially been treated with tamoxifen before switching to an aromatase inhibitor.
11European Journal of Cancer. 10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysisThis is where genomic tests are entering the conversation. The Breast Cancer Index is a test that provides both prognostic information (how likely is recurrence?) and predictive information (would this specific patient benefit from extended therapy?). In the NSABP B-42 trial, women classified as high-risk by the Breast Cancer Index showed a dramatic benefit from extended letrozole, while low-risk women saw no statistically significant benefit.
12PubMed Central. Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial Another tool, the Clinical Treatment Score at 5 Years, estimates late recurrence risk but does not predict who will specifically benefit from more therapy, a distinction that matters when you are weighing side effects against protection.13Archives of Breast Cancer. Real-World Experience Using the Clinical Treatment Score at 5 Years (CTS5) and Breast Cancer Index (BCI) to Guide Extended Adjuvant Endocrine Therapy
If you stopped at five years and your oncologist agreed that was appropriate for your risk profile, second-guessing the decision is understandable but usually unwarranted. If you were not offered a genomic test and have lingering worry, it is reasonable to ask at a follow-up whether one could still be informative.
What Happens If You Stopped Early
Not everyone completes the full course. Side effects drive a substantial number of women to stop ahead of schedule. In one study, about 22% of premenopausal women discontinued endocrine therapy before the recommended duration. Among those who stopped early, recurrence rates were roughly 20%, compared with about 11% in women who completed treatment.
14Clinical Cancer Research. Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal WomenThose numbers are sobering but need context. The increased risk is a population average, and individual risk depends on tumor characteristics, stage, and how much of the therapy was completed. Stopping after four years is a very different scenario than stopping after one year. If you discontinued early, the most productive step is an honest conversation with your oncologist about your specific situation and whether any alternative strategies, such as switching to a different endocrine agent with more tolerable side effects, might be worth considering.
Post-Treatment Monitoring
Once you finish letrozole, your follow-up schedule simplifies considerably. The primary surveillance for breast cancer recurrence in the post-treatment period involves annual mammography. Routine blood work and imaging scans to hunt for metastatic disease are not recommended for women who have no symptoms, because studies have consistently shown that intensive surveillance does not improve outcomes compared with symptom-directed investigation. Screening for other cancers should follow the same guidelines as for the general population.
15PubMed Central. Follow-up after treatment for breast cancer: Practical guide to survivorship care for family physiciansThis stripped-down approach can feel unsettling after years of frequent oncology appointments. Many women experience a spike in anxiety precisely because the safety net of active treatment is gone. If you notice new or persistent symptoms, such as bone pain, unexplained weight loss, or a new lump, bring them to your doctor promptly rather than waiting for a scheduled appointment. But the absence of routine scans is not a gap in your care. It is evidence-based medicine working as intended.
Exercise and the Transition Period
Physical activity after breast cancer treatment has well-established benefits for physical and emotional well-being, bone health, lymphedema management, and potentially for reducing the risk of recurrence.
16PubMed Central. Exercise after breast cancer treatment: current perspectives The post-letrozole period is a particularly good window to ramp up activity, because the joint pain and stiffness that may have limited you during treatment will be fading.
Resistance training matters at least as much as cardio in this context. Your bones are recovering but still vulnerable, and weight-bearing exercise is one of the most effective non-pharmacological ways to support bone density. Starting slowly and building up is important, especially if you were relatively sedentary during treatment. A physiotherapist or exercise physiologist with experience in cancer rehabilitation can help you build a program that accounts for any lingering effects of treatment, such as reduced range of motion from surgery or lymphedema precautions.
The psychological benefit of exercise in this period tends to be underappreciated. Finishing treatment can trigger an identity shift: you go from being a patient to being a survivor, and many women describe feeling oddly adrift. Regular physical activity provides structure, tangible progress, and a sense of agency over your body that five years of cancer treatment may have eroded. It is not a cure for existential anxiety, but it is one of the few interventions that simultaneously addresses bone health, cardiovascular fitness, mood, and that hard-to-name feeling of wanting your body back.